Clinical Trial Update: MB-CART19.1 in Patients With R/R ALL [Phase 2]

View source ↗

Summary

This document notes a Phase 2 clinical trial evaluating MB-CART19.1 in patients with refractory precursor B-cell acute lymphoblastic leukemia, with the trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Precursor B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• MB-CART19.1

Snippet

Sponsor: Shanghai Children's Medical Center | Conditions: Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory | Phase 2 | Status: UNKNOWN